Abstract
Iron oxide (IO) nanoparticles hold great promise as diagnostic and therapeutic agents in oncology. Their intrinsic physical properties make IO nanoparticles particularly interesting for simultaneous drug delivery, molecular imaging, and applications such as localized hyperthermia. Multiple non-targeted IO nanoparticle preparations have entered clinical trials, but more exciting, new tumortargeted IO nanoparticle preparations are currently being tested in preclinical settings. This paper will analyze the challenges faced by this new theranostic modality, with a specific focus on the interactions of IO nanoparticles with the innate and adaptive immune systems, and their effect on nanoparticle biodistribution and tumor targeting. Next, we will review the critical need for innovative surface chemistry solutions and strategies to overcome the immune interactions that prevent existing tumor-targeted IO preparations from entering clinical trials. Finally, we will provide an outlook for the future role of IO nanoparticles in oncology, which have the promise of becoming significant contributors to improved diagnosis and treatment of cancer patients.
Keywords: Iron oxide nanoparticles, tumor targeting, immunology, inflammation, macrophage, nanoparticle surface chemistry, cancer theranostics.
Current Pharmaceutical Design
Title:Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Volume: 19 Issue: 37
Author(s): Dana C. Baiu, Christopher S. Brazel, Yuping Bao and Mario Otto
Affiliation:
Keywords: Iron oxide nanoparticles, tumor targeting, immunology, inflammation, macrophage, nanoparticle surface chemistry, cancer theranostics.
Abstract: Iron oxide (IO) nanoparticles hold great promise as diagnostic and therapeutic agents in oncology. Their intrinsic physical properties make IO nanoparticles particularly interesting for simultaneous drug delivery, molecular imaging, and applications such as localized hyperthermia. Multiple non-targeted IO nanoparticle preparations have entered clinical trials, but more exciting, new tumortargeted IO nanoparticle preparations are currently being tested in preclinical settings. This paper will analyze the challenges faced by this new theranostic modality, with a specific focus on the interactions of IO nanoparticles with the innate and adaptive immune systems, and their effect on nanoparticle biodistribution and tumor targeting. Next, we will review the critical need for innovative surface chemistry solutions and strategies to overcome the immune interactions that prevent existing tumor-targeted IO preparations from entering clinical trials. Finally, we will provide an outlook for the future role of IO nanoparticles in oncology, which have the promise of becoming significant contributors to improved diagnosis and treatment of cancer patients.
Export Options
About this article
Cite this article as:
C. Baiu Dana, S. Brazel Christopher, Bao Yuping and Otto Mario, Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology, Current Pharmaceutical Design 2013; 19 (37) . https://dx.doi.org/10.2174/13816128113199990409
DOI https://dx.doi.org/10.2174/13816128113199990409 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanocellulose and its Composites for Biomedical Applications
Current Medicinal Chemistry Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Intracranial Aneurysms; In Need of Early Diagnostic and Treatment Using Bio- and Nanotechnology
Current Medicinal Chemistry Recent Patents on Biomedical Devices and Nanomaterials for Hyperthermal Therapy of Cancer
Recent Patents on Nanomedicine Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis
Current Cardiology Reviews Coarctation of the Aorta - An Evolution of Therapeutic Options
Current Cardiology Reviews A Novel Therapeutic Strategy Against Vascular Disorders with Chymase Inhibitor
Current Vascular Pharmacology Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design All for Statins and Statins for All; An Update
Current Pharmaceutical Design Contributory Role of Matrix Metalloproteinases in Cardiovascular Remodeling
Current Drug Targets - Cardiovascular & Hematological Disorders Atrial Tachycardias Arising from the Atrial Appendages and Aortic Sinus of Valsalva
Current Cardiology Reviews An Evidence-Based Review of Off-Label Uses of Polidocanol
Current Clinical Pharmacology Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Impact of Dysfunctional Protein Catabolism on Macrophage Cholesterol Handling
Current Medicinal Chemistry Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design Cardiac Tissue Engineering
Recent Patents on Regenerative Medicine Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets